clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИclinvest-95Research ArticleАКТУАЛЬНЫЕ ОБЗОРЫACTUAL REVIEWОсновные показания к применению пероральных антикоагулянтов: как выбрать оптимальный препаратMain indications for peroral anticoagulants: how to choose an optimal drugЯвеловИ. С.YavelovI. S.yavelov@yahoo.comФГБУ «НМИЦ профилактической медицины» МЗ РФ; ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» МЗ РФРоссияFSI “National Medical Research Center for Preventive Medicine”; FGBOU VP RNRMU named after Pirogova N.IRussian Federation201716052018035360Copyright © Явелов И.С., 20182018Явелов И.С.Yavelov I.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/95

В статье рассматриваются практически важные особенности использования пероральных антикоагулянтов в профилактике и лечении тромботических и тромбоэмболических осложнений у больных с фибрилляцией предсердий, при венозных тромбоэмболических осложнениях и ишемической болезни сердца. Сопоставляются основные фармакологические особенности варфарина и пероральных антикоагулянтов прямого действия, а также результаты сравнения их эффективности и безопасности в рамках проспективных рандомизированных контролируемых исследований. Указываются категории больных, у которых данные о результатах применения пероральных антикоагулянтов прямого действия ограничены или отсутствуют.

Practical approaches to use of oral anticoagulants for prevention and treatment of thrombotic and thromboembolic complications in patients with atrial fibrillation, venous thromboembolism and coronary heart disease are considered. Comparison of main pharmacologic properties of DOACs and warfarin as well as their efficacy and safety in prospective randomized controlled trials are present. Clinical situations with minimal or no evidence for use of DOACs are specified.

пероральные антикоагулянтыапиксабандабигатрана этексилатривароксабанварфаринperoral anticoagulantsapixabandabigatranrivaroxabanwarfarinReferencesHeidbuchel H., Verhamme P., Alings M., et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015; 17: 1467-1507.Heidbuchel H., Verhamme P., Alings M., et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015; 17: 1467-1507.Salmonson T., Dogné J.-M., Janssen H., et al. Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future. Views from a workshop at the European Medicines Agency (EMA). EurHYPERLINK «https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216197/» Heart J Cardiovasc HYPERLINK «https:// www.ncbi.nlm.nih.gov/pmc/articles/PMC5216197/»Pharmacother. 2017; 3: 42-47.Salmonson T., Dogné J.-M., Janssen H., et al. Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future. Views from a workshop at the European Medicines Agency (EMA). EurHYPERLINK «https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216197/» Heart J Cardiovasc HYPERLINK «https:// www.ncbi.nlm.nih.gov/pmc/articles/PMC5216197/»Pharmacother. 2017; 3: 42-47.Konstantinides S., Torbicki A., Agnelli G., et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Endorsed by the European Respiratory Society (ERS). Eur Heart J. 2014; 35: 3033-3069.Konstantinides S., Torbicki A., Agnelli G., et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Endorsed by the European Respiratory Society (ERS). Eur Heart J. 2014; 35: 3033-3069.Kearon C., Akl E.A., Ornelas J., et al. Antithrombotic Therapy for VTE Disease. Chest Guideline and Expert Panel Report. Chest. 2016; 149: 315-352.Kearon C., Akl E.A., Ornelas J., et al. Antithrombotic Therapy for VTE Disease. Chest Guideline and Expert Panel Report. Chest. 2016; 149: 315-352.Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016; 50: e1-e88.Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016; 50: e1-e88.Roffi M., Patrono C., Collet J.P., et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37: 267-315.Roffi M., Patrono C., Collet J.P., et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37: 267-315.Schulman S., Kearon C., Kakkar A.K., et al., for the RE-COVER Study Group. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. N Engl J Med. 2009; 361: 2342-2352.Schulman S., Kearon C., Kakkar A.K., et al., for the RE-COVER Study Group. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. N Engl J Med. 2009; 361: 2342-2352.Schulman S., Kakkar A.K., Goldhaber S.Z., et al., for the RE-COVER II trial investigators. Treatment of Acute Venous Thromboembolism with Dabigatran or Warfarin and Pooled Analysis. Circulation. 2014; 129: 764-772.Schulman S., Kakkar A.K., Goldhaber S.Z., et al., for the RE-COVER II trial investigators. Treatment of Acute Venous Thromboembolism with Dabigatran or Warfarin and Pooled Analysis. Circulation. 2014; 129: 764-772.The EINSTEIN Investigators. Oral Rivaroxaban for Symptomatic Venous Thromboembolism. N Engl J Med. 2010; 363: 2499-2510.The EINSTEIN Investigators. Oral Rivaroxaban for Symptomatic Venous Thromboembolism. N Engl J Med. 2010; 363: 2499-2510.The EINSTEIN-PE Investigators. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. N Engl J Med. 2012; 366: 1287-1297.The EINSTEIN-PE Investigators. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. N Engl J Med. 2012; 366: 1287-1297.Agnelli G., Buller H.R., Cohen A., et al., for the AMPLIFY Investigators. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. N Engl J Med. 2013; 369: 799-808.Agnelli G., Buller H.R., Cohen A., et al., for the AMPLIFY Investigators. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. N Engl J Med. 2013; 369: 799-808.Werth S., Bauersachs R., Gerlach H., Rabe E., et al. Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. J Thromb Thrombol. 2016; 42: 197-204.Werth S., Bauersachs R., Gerlach H., Rabe E., et al. Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. J Thromb Thrombol. 2016; 42: 197-204.Connolly S.J., Ezekowitz M.D., Yusuf S., et al., the RE-LY Steering Committee and Investigators. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009; 361: 1139-1151.Connolly S.J., Ezekowitz M.D., Yusuf S., et al., the RE-LY Steering Committee and Investigators. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009; 361: 1139-1151.Granger C.B., Alexander J.H., McMurray J.J., et al., for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-992.Granger C.B., Alexander J.H., McMurray J.J., et al., for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-992.Patel M.R., Mahaffey K.W., Garg J., et al., for the ROCKET-AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-891.Patel M.R., Mahaffey K.W., Garg J., et al., for the ROCKET-AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-891.Mega J.L., BraunwaldHYPERLINK «http://www.ncbi.nlm.nih.gov/pubmed/?term=Braunwald%20E%5BAuthor%5D&cauthor=true&cauthor_uid=22077192» E., WiviottHYPERLINK «http://www.ncbi.nlm.nih.gov/pubmed/?term=Wiviott%20SD%5BAuthor%5D&cauthor=true&cauthor_uid=22077192» S.D., et al.; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N HYPERLINK «http://www.ncbi.nlm.nih.gov/ pubmed/22077192»EnglHYPERLINK «http://www.ncbi.nlm.nih.gov/pubmed/22077192» J Med. 2012; 366: 9-19.Mega J.L., BraunwaldHYPERLINK «http://www.ncbi.nlm.nih.gov/pubmed/?term=Braunwald%20E%5BAuthor%5D&cauthor=true&cauthor_uid=22077192» E., WiviottHYPERLINK «http://www.ncbi.nlm.nih.gov/pubmed/?term=Wiviott%20SD%5BAuthor%5D&cauthor=true&cauthor_uid=22077192» S.D., et al.; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N HYPERLINK «http://www.ncbi.nlm.nih.gov/ pubmed/22077192»EnglHYPERLINK «http://www.ncbi.nlm.nih.gov/pubmed/22077192» J Med. 2012; 366: 9-19.Lip G.Y., Windecker S., Huber K., et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014; 35: 3155-3179.Lip G.Y., Windecker S., Huber K., et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014; 35: 3155-3179.Dans A.L., Connolly S.J., Wallentin L., et al. Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. Circulation. 2013; 127: 634-640.Dans A.L., Connolly S.J., Wallentin L., et al. Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. Circulation. 2013; 127: 634-640.Gibson C.M., Mehran R., Bode C., et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016; 375: 2423-2434.Gibson C.M., Mehran R., Bode C., et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016; 375: 2423-2434.

The authors declare that there are no conflicts of interest present.